Hypophosphatemia is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.
A decrease in serum phosphate should be distinguished from a decrease in total body storage of phosphate.
Hypophosphatemia may be transient and reflect intracellular shift with minimal clinical consequences.
Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.
The significant level of hyperphosphatemia in adults is 5 mg/dL.
The cost-effectiveness of sevelamer compared to calcium carbonate in the first-line treatment of hyperphosphataemia among new haemodialysis patients is presented in a patient-level, economic evaluation of the INDEPENDENT-HD study.
Sucroferric oxyhydroxide seems to be more cost-effective than sevelamer carbonate in hyperphosphataemia patients on dialysis who are intolerant to calcium-based phosphate binder based on a study from the perspective of the Scottish National Health Service.
Global hypomethylation of Alu appears to increasingly influence distant metastatic differentiated thyroid cancer (DTC), poorly (P)DTC and anaplastic (A)TC, according to a recent study. This suggests that the epigenetic entity may be involved in thyroid cancer progression and dedifferentiation.